Skip to Main Content
PallMed.Net
Welcome to the Home of PCIC Podcasts !
Home > Leaders > ASCO LDP Faculty > Melvin Lee Kiang Chua

Please Leave a Review or Suggestion Cancel reply

Your email address will not be published. Required fields are marked *

No Comments

Melvin Lee Kiang Chua

Melvin Lee Kiang Chua, MBBS, FRCR, PhD, FAMS

Chair, Department of Head and Neck and Thoracic Cancers,
Senior consultant, Clinician-Scientist,
Division of Radiation Oncology

National Cancer Centre Singapore
11 Hospital Crescent 

Singapore 169610
Phone / Email Information
Email: melvin.chua.09@alumni.ucl.ac.uk or gmsclkm@nus.edu.sg

About

Dr. Chua is a Clinician-Scientist, who is supported by the NMRC Clinician-Scientist Award. His research focuses on the development of Ph II-III clinical trials in nasopharyngeal (NPC) and prostate cancers. He also runs a laboratory that is involved in data science and omics analytics that help with therapeutic and biomarker discovery for these cancer types.

Other Appointments

  • Principal Investigator, Tan Chin Tuan Laboratory of Optical Imaging, Photodynamic and Proton Therapy – Precision Radiation Oncology Programme, National Cancer Centre Singapore
  • Director, Data and Computational Science Core, National Cancer Centre Singapore
  • Associate Professor (Tenured), Duke-NUS Medical School, Singapore
  • Visiting Professor, Zhongnan Hospital of Wuhan University, China

Key Accomplishments

  • ASCO-CSCO International guidelines on the treatment of locoregionally-advanced NPC, which was published in the Journal of Clinical Oncology
  • Co-Lead investigator of the randomised controlled trial of induction gemcitabine-cisplatin in high-risk locoregionally-advanced NPC, which defined the new standard-of-care (research was published in the New England Journal of Medicine)
  • Co-Lead investigator of the randomised controlled trial of consolidation radiotherapy in patients with metastatic NPC who manifest a good response to palliative chemotherapy. This study again defined a new standard-of-care in these patients (published in JAMA Oncology)
  • Developed a web-based, free-to-use tool to stratify patients with locoregionally recurrent NPC for re-irradiation (PRANCIS: Prediction of RAdioresistant Nasopharyngeal CarcInoma Survival; ww.PRANCIS.Medlever.com). This is impactful, given that 50% of death events in this patient subgroup are due to re-treatment toxicities (published in the Journal of Clinical Oncology)

Education / Honors

  • NMRC Clinician-Scientist Award (Investigator), 2015, 2018, 2021
  • Fellow of the Academy of Medicine Singapore (FAMS), The College of Radiation Oncology and Clinician Scientists, Singapore, 2021
  • Conquer Cancer Foundation ASCO Merit Award, 2017, 2016, 2013
  • Doctor of Philosophy (PhD), University College London, UK, 2013
  • Fellow of the Royal College of Radiologists (FRCR for Clinical Oncology), The Royal College of Radiologists, UK, 2013
  • Privacy Policy
  • Terms and Conditions
  • Accessibility Statement

PCIC podcasts do not replace careful clinical judgement specific to each patient / family situation. ALWAYS use your careful clinical judgement when caring for each patient and family.

  • Email Us

© 2023 PallMed.Net

Newsletter Signup

We will never, ever sell your email address or use it for anything else other than our newsletter.


We use Campaign Monitor for email marketing. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to Campaign Monitor for processing in accordance with their Terms of Use Policy.

PallMed.Net uses cookies. For more information on our cookie policy see our privacy policy. By closing this message or continuing to browse PallMed.Net, you are agreeing to our use of cookies on this browser.

Back to Top